Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-08 00:18 | 2025-02-05 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $62.50 | 2,500 | $156,250 | 26,595 | -8.6% |
| 2024-11-26 00:05 | 2024-11-22 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $60.00 | 2,500 | $150,000 | 26,595 | -8.6% |
| 2024-11-14 00:05 | 2024-11-11 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $56.25 | 5,000 | $281,250 | 26,595 | -15.8% |
| 2024-03-29 23:05 | 2024-03-27 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $51.57 | 3,278 | $169,046 | 23,395 | -12.3% |
| 2024-02-23 00:07 | 2024-02-20 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $50.01 | 722 | $36,107 | 23,395 | -3.0% |
| 2024-01-31 00:05 | 2024-01-29 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $44.22 | 2,300 | $101,706 | 23,395 | -9.0% |
| 2024-01-30 00:05 | 2024-01-25 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $44.02 | 200 | $8,804 | 25,695 | -0.8% |
| 2024-01-25 00:05 | 2024-01-22 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $41.85 | 8,000 | $334,775 | 25,895 | -23.6% |
| 2024-01-17 00:05 | 2024-01-12 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $38.09 | 2,200 | $83,798 | 30,895 | -6.6% |
| 2023-11-18 00:06 | 2023-11-15 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $38.02 | 300 | $11,406 | 33,095 | -0.9% |
| 2023-07-17 23:05 | 2023-07-14 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $38.84 | 1,000 | $38,840 | 33,395 | -2.9% |
| 2023-06-26 23:05 | 2023-06-22 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $36.00 | 3,000 | $108,000 | 34,395 | -8.0% |
| 2020-11-25 00:09 | 2020-11-23 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $23.55 | 17,500 | $412,125 | 31,795 | -35.5% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.